NASDAQ:FBIO

Fortress Biotech News Headlines

$4.30
+0.10 (+2.38 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.13
Now: $4.30
$4.53
50-Day Range
$3.40
MA: $4.20
$5.48
52-Week Range
$1.89
Now: $4.30
$6.10
Volume1.59 million shs
Average Volume1.68 million shs
Market Capitalization$408.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43

Headlines

Fortress Biotech (NASDAQ FBIO) News Headlines Today

SourceHeadline
Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing SummitMustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
finance.yahoo.com - April 21 at 8:46 AM
Fortress Biotech (NASDAQ:FBIO) PT Raised to $5.00 at Roth CapitalFortress Biotech (NASDAQ:FBIO) PT Raised to $5.00 at Roth Capital
americanbankingnews.com - April 20 at 10:08 AM
NOTICE For Investors In NASDAQ: FBIO Shareholder Notice: Lawsuit against Fortress Biotech, Inc announced by Shareholders FoundationNOTICE For Investors In NASDAQ: FBIO Shareholder Notice: Lawsuit against Fortress Biotech, Inc announced by Shareholders Foundation
finance.yahoo.com - April 20 at 7:14 AM
Zacks: Analysts Expect Fortress Biotech, Inc. (NASDAQ:FBIO) Will Post Quarterly Sales of $13.41 MillionZacks: Analysts Expect Fortress Biotech, Inc. (NASDAQ:FBIO) Will Post Quarterly Sales of $13.41 Million
americanbankingnews.com - April 20 at 3:36 AM
Fortress Biotech, Inc. (NASDAQ:FBIO) Expected to Announce Earnings of -$0.21 Per ShareFortress Biotech, Inc. (NASDAQ:FBIO) Expected to Announce Earnings of -$0.21 Per Share
americanbankingnews.com - April 18 at 2:06 PM
Why Fortress Biotech Stock Is Sinking TodayWhy Fortress Biotech Stock Is Sinking Today
finance.yahoo.com - April 13 at 4:06 PM
Fortress Biotech (NASDAQ:FBIO) Shares Gap Down to $5.48Fortress Biotech (NASDAQ:FBIO) Shares Gap Down to $5.48
americanbankingnews.com - April 13 at 11:20 AM
Avenue Therapeutics: FDA Still Reviewing NDA Resubmission - Quick FactsAvenue Therapeutics: FDA Still Reviewing NDA Resubmission - Quick Facts
nasdaq.com - April 13 at 8:32 AM
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV TramadolAvenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
finance.yahoo.com - April 13 at 8:32 AM
Fortress Biotech, Inc. (NASDAQ:FBIO) Given Average Rating of "Buy" by AnalystsFortress Biotech, Inc. (NASDAQ:FBIO) Given Average Rating of "Buy" by Analysts
americanbankingnews.com - April 13 at 4:34 AM
Fortress Gains after Friday JumpFortress Gains after Friday Jump
baystreet.ca - April 12 at 2:12 PM
Is the Options Market Predicting a Spike in Fortress Biotech (FBIO) Stock?Is the Options Market Predicting a Spike in Fortress Biotech (FBIO) Stock?
finance.yahoo.com - April 12 at 2:12 PM
Fortress Biotech (NASDAQ:FBIO) Shares Gap Up to $5.44Fortress Biotech (NASDAQ:FBIO) Shares Gap Up to $5.44
americanbankingnews.com - April 12 at 11:44 AM
Fortress Biotech (FBIO) Surges 11.5%: Is This an Indication of Further Gains?Fortress Biotech (FBIO) Surges 11.5%: Is This an Indication of Further Gains?
finance.yahoo.com - April 12 at 8:02 AM
Fortress Biotech Target of Unusually High Options Trading (NASDAQ:FBIO)Fortress Biotech Target of Unusually High Options Trading (NASDAQ:FBIO)
americanbankingnews.com - April 9 at 8:52 PM
Fortress Biotech, Inc. (NASDAQ:FBIO) Director Sells $44,500.00 in StockFortress Biotech, Inc. (NASDAQ:FBIO) Director Sells $44,500.00 in Stock
americanbankingnews.com - April 9 at 7:50 PM
Eric K. Rowinsky Sells 6,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) StockEric K. Rowinsky Sells 6,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) Stock
americanbankingnews.com - April 9 at 7:50 PM
Fortress Biotech, Inc. (NASDAQ:FBIO) Director Eric K. Rowinsky Sells 4,000 SharesFortress Biotech, Inc. (NASDAQ:FBIO) Director Eric K. Rowinsky Sells 4,000 Shares
americanbankingnews.com - April 9 at 7:50 PM
Fortress Biotech (NASDAQ:FBIO) Sets New 52-Week High at $5.78Fortress Biotech (NASDAQ:FBIO) Sets New 52-Week High at $5.78
americanbankingnews.com - April 9 at 7:09 PM
Brokers Set Expectations for Fortress Biotech, Inc.s FY2021 Earnings (NASDAQ:FBIO)Brokers Set Expectations for Fortress Biotech, Inc.'s FY2021 Earnings (NASDAQ:FBIO)
americanbankingnews.com - April 7 at 6:36 AM
Best Penny Stocks to Buy Right Now? 3 To Watch As Biotech ReboundsBest Penny Stocks to Buy Right Now? 3 To Watch As Biotech Rebounds
marketwatch.com - April 5 at 2:41 PM
Journey Medical Corporation Enters $7.5 Million Line of Credit Agreement with East West BankJourney Medical Corporation Enters $7.5 Million Line of Credit Agreement with East West Bank
finance.yahoo.com - April 5 at 9:41 AM
Fortress Biotechs (FBIO) Buy Rating Reaffirmed at B. RileyFortress Biotech's (FBIO) Buy Rating Reaffirmed at B. Riley
americanbankingnews.com - April 5 at 8:40 AM
Fortress Biotech, Inc. (NASDAQ:FBIO) Annual Results: Heres What Analysts Are Forecasting For This YearFortress Biotech, Inc. (NASDAQ:FBIO) Annual Results: Here's What Analysts Are Forecasting For This Year
nasdaq.com - April 3 at 2:24 PM
Cantor Fitzgerald Reiterates Overweight Rating for Fortress Biotech (NASDAQ:FBIO)Cantor Fitzgerald Reiterates Overweight Rating for Fortress Biotech (NASDAQ:FBIO)
americanbankingnews.com - April 2 at 9:26 AM
Zacks: Analysts Anticipate Fortress Biotech, Inc. (NASDAQ:FBIO) Will Announce Quarterly Sales of $11.34 MillionZacks: Analysts Anticipate Fortress Biotech, Inc. (NASDAQ:FBIO) Will Announce Quarterly Sales of $11.34 Million
americanbankingnews.com - April 2 at 1:32 AM
Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®
finance.yahoo.com - April 1 at 9:38 AM
Fortress Biotech (NASDAQ:FBIO) Posts  Earnings ResultsFortress Biotech (NASDAQ:FBIO) Posts Earnings Results
americanbankingnews.com - April 1 at 8:34 AM
Best Penny Stocks To Buy On Robinhood? 3 Biotechs For Your Watch ListBest Penny Stocks To Buy On Robinhood? 3 Biotechs For Your Watch List
marketwatch.com - March 27 at 12:12 AM
Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular AcneFortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne
finance.yahoo.com - March 22 at 12:16 PM
Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?
finance.yahoo.com - March 17 at 9:03 AM
Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate HighlightsCheckpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 9 at 5:39 PM
NASDAQ: FBIO Investor Notice: Lawsuit against Fortress Biotech, Inc. announced by Shareholders FoundationNASDAQ: FBIO Investor Notice: Lawsuit against Fortress Biotech, Inc. announced by Shareholders Foundation
finance.yahoo.com - March 9 at 12:39 PM
Will Fortress Biotech (FBIO) Report Negative Q4 Earnings? What You Should KnowWill Fortress Biotech (FBIO) Report Negative Q4 Earnings? What You Should Know
finance.yahoo.com - March 8 at 1:40 PM
Mustang Bio to Participate in Three March 2021 Virtual Investor ConferencesMustang Bio to Participate in Three March 2021 Virtual Investor Conferences
finance.yahoo.com - March 4 at 8:36 AM
Fortress Biotech to Participate in Four March 2021 Virtual Investor ConferencesFortress Biotech to Participate in Four March 2021 Virtual Investor Conferences
finance.yahoo.com - March 4 at 8:36 AM
Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual ConferenceCheckpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference
finance.yahoo.com - March 4 at 8:36 AM
Thinking about buying stock in ConforMIS, Inuvo, Rocket Companies, Fortress Biotech, or Perion Network?Thinking about buying stock in ConforMIS, Inuvo, Rocket Companies, Fortress Biotech, or Perion Network?
marketwatch.com - March 2 at 11:26 AM
Checkpoint Therapeutics Announces Formation of Scientific Advisory BoardCheckpoint Therapeutics Announces Formation of Scientific Advisory Board
finance.yahoo.com - March 1 at 12:36 PM
Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day(R)Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day(R)
marketwatch.com - February 27 at 1:43 AM
Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
finance.yahoo.com - February 26 at 10:12 AM
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
finance.yahoo.com - February 26 at 10:12 AM
Fortress Biotechs Partner Offloads CUTX-101 To Sentynl TherapeuticsFortress Biotech's Partner Offloads CUTX-101 To Sentynl Therapeutics
finance.yahoo.com - February 24 at 3:27 PM
Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes DiseaseCyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes Disease
finance.yahoo.com - February 24 at 9:17 AM
Fortress Biotech CEO Explains The Companys Three-Step Business ModelFortress Biotech CEO Explains The Company's Three-Step Business Model
finance.yahoo.com - February 23 at 2:07 PM
Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive OfficerAevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer
finance.yahoo.com - February 22 at 2:18 PM
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
finance.yahoo.com - February 2 at 12:29 PM
FBIO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors With Losses Exceeding $600,000 of Class Action and Lead Plaintiff Deadline: January 26, 2021FBIO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors With Losses Exceeding $600,000 of Class Action and Lead Plaintiff Deadline: January 26, 2021
finance.yahoo.com - January 26 at 6:45 PM
FBIO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021FBIO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021
finance.yahoo.com - January 26 at 1:45 PM
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmDEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Fortress Biotech, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
finance.yahoo.com - January 26 at 8:44 AM
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.